Nitric oxide (NO) is a versatile messenger molecule first associated with endothelial relaxing effects. In the central nervous system (CNS), NO synthesis is primarily triggered by activation of N-methyl-D-aspartate (NMDA) receptors and has a Janus face, with both beneficial and harmful properties. There are three isoforms of the NO synthesizing enzyme nitric oxide synthase (NOS): neuronal (nNOS), endothelial (eNOS), and inducible nitric oxide synthase (iNOS), each one involved with specific events in the brain. In the CNS, nNOS is involved with modulation of synaptic transmission through long-term potentiation in several regions, including nociceptive circuits in the spinal cord. Here, we review the role played by NO on central pain sensitization.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2751623 | PMC |
| http://dx.doi.org/10.3389/neuro.01.024.2009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Muscarinic acetylcholine receptor 3 localized to primary endothelial cilia regulates blood pressure and cognition.
Sci Rep
January 2025
Department of Pharmacology and Experimental Therapeutics; MS 1015, College of Pharmacy and Pharmaceutical Sciences, The University of Toledo, Health Education Building; Room 282E, 3000 Arlington Ave, Toledo, OH, 43614, USA.
We previously demonstrated that the inability of primary endothelial cilia to sense fluid shear stress can lead to nitric oxide (NO) deficiency and cause hypertension (HTN). Decreased biosynthesis of NO contributes to cerebral amyloid angiopathy in Alzheimer's disease (AD) patients through increased deposition of amyloid beta (Aβ). However, the molecular mechanisms underlying the pathogenesis of HTN and AD are incompletely understood.
View Article and Find Full Text PDFExploring acemannan-loaded nanogel formulation for the treatment of IMQ-induced psoriasis-like inflammation: In vitro characterization and in vivo efficacy assessment.
Int Immunopharmacol
January 2025
Department of Biochemistry, Faculty of Sciences, King Abdulaziz University, Jeddah 21589 Saudi Arabia. Electronic address:
This study aimed to explore a nanogel formulation containing acemannan as a carrier for the treatment of psoriasis-like skin inflammation. Several acemannan concentrations, such as F1 (2.5 %) and F2 (5 %), were used to prepare the nanogel formulation by homogenization.
View Article and Find Full Text PDFA proof-of-mechanism trial in asthma with lunsekimig, a bispecific nanobody® molecule.
Eur Respir J
January 2025
Sanofi, Bridgewater, NJ, USA.
Background: Monovalent biologics blocking thymic stromal lymphopoietin or interleukin-13 have been shown to elicit pharmacodynamic responses in asthma following a single dose. Therefore, dual blockade of these cytokines may result in an enhanced response compared to single targeting and has the potential to break efficacy ceilings in asthma. This study assessed the safety and tolerability of lunsekimig, a bispecific NANOBODY molecule that blocks thymic stromal lymphopoietin and interleukin-13, and its effect on Type 2 inflammatory biomarkers and lung function in asthma.
View Article and Find Full Text PDFThis Month in JAAD International: April 2025: Options of molluscum contagiosum management.
J Am Acad Dermatol
January 2025
From the Department of Dermatology, Center for Global Health, and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania and Florida Center for Dermatology, St Augustine, Florida. Electronic address:
Innate immune function in chronic rhinosinusitis.
J Allergy Clin Immunol
January 2025
Division of Rhinology, Department of Otorhinolaryngology, University of Pennsylvania Perelman School of Medicine; Monell Chemical Senses Center, Philadelphia; PA; Corporal Michael J. Crescenz Veterans Administration Medical Center, Philadelphia, PA. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!